Table 4.
Summary table of response rates in GOG phase II trial of various chemotherapy agents in advanced uterine leiomyosarcoma.
| GOG phase II study principal investigator, reference | Drug | # prior regimens | Objective Response rate |
|---|---|---|---|
| McMeekin19 | thalidomide | 1 | 0/29 (0%) |
| Look27 | gemcitabine | 0−1 | 9/42 (20%) |
| Sutton3 | liposomal doxorubicin | 0 | 5/32 (16%) |
| Gallup17 | paclitaxel | 0−1 | 4/48 (8%) |
| Sutton18 | paclitaxel | 0 | 3/33 (9%) |
| Thigpen16 | cisplatin | 0 | 1/33 (3%) |
| Sutton3 | doxorubicin | 0 | 7/28 (25%) |
| Sutton5 | ifosfamide | 0 | 6/35(17%) |
| Thigpen34 | etoposide IV | 0 | 0/28 (0%) |
| Rose13 | etoposide PO | 1 | 2/29 (7%) |
| Miller16 | topotecan | 0 | 4/36 (11%) |
| Smith20 | trimetrexate | 0−1 | 1/23 (4%) |
| GOG 87L (Hensley)* | gemcitabine + docetaxel | 0 | 15/42 (36%) |
*
GOG 87L is the study whose results are the subject of this report.